MindMaze Receives Recognition as one of Switzerland’s Best Managed Companies
8.7.2022 17:00:00 EEST | Business Wire | Press release
MindMaze, a global pioneer in neurotechnology and digital therapeutics (DTx) for neurological recovery and care, has been recognized as one of Switzerland’s Best Managed Companies in 2022. This programme, sponsored by Deloitte Private, SIX Swiss Exchange, and Julius Baer, awards Swiss companies who operate at the highest level of business performance.
“We are thrilled to receive this distinguished recognition for our efforts,” said COO of MindMaze, Jean-Marc Wismer. “As a team we are focused on innovation and quality because when it comes to developing groundbreaking technologies and therapies to treat those suffering from neurological conditions and injuries, good business practices and processes are vital to attract and retain great talent and grow sustainably.”
Switzerland’s Best Managed Companies Programme highlights exceptional business practices executed by Switzerland’s best privately owned companies. A company’s efforts, overall growth, and management abilities factor into the programme’s selection. The Deloitte evaluation for these awards is based on 29 years of observed practice from the global awards programme that has been rolled out in 48 countries worldwide. Companies that are chosen for this award are upheld as examples for other businesses to follow.
The company’s unique organizational model supports both rapid scalability and allows for greater flexibility in a changing environment. This model has proven to be highly effective particularly through COVID, enabling the company to seamlessly adapt its business model to balance product development, marketing and sales activities and maintain strong revenue growth with continued expansion of commercial operations across 15 countries. “Deloitte’s recognition further validates our agile governance hierarchy, which focuses on roles instead of titles,” adds Wismer. “Cultivating an atmosphere of collaboration and accountability has allowed us to form efficient and ethical business practices that benefit the company, its employees, and our stakeholders.”
About MindMaze
Founded in 2012, MindMaze is a global leader in brain technology and digital neurotherapeutic solutions for brain health and recovery. Its mission is to accelerate the brain’s ability to recover, learn and adapt. The company has two core divisions – Healthcare and Labs – working collaboratively at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence. MindMaze Healthcare is advancing a universal platform for brain health with breakthrough solutions to some of the world’s most challenging problems in neurology, including stroke, Parkinson’s disease and Alzheimer’s disease. MindMaze Labs, the company’s R&D innovation hub, is focused on the future of human computing – working across multiple industries to innovate and build the next generation of human-machine interfaces. The company has offices in Lausanne, Baltimore, London, Paris and Mumbai. For more information, please visit www.mindmaze.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220708005284/en/
Contact information
MindMaze
Public Relations
Phoebe Alix
E: pr@mindmaze.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 16:38:00 EET | Press release
Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net profit was at €250.9 million. In 2024, the corresponding value was €211.1 million. Following the results achieved in 2025, the Reply Board of Directors decided to propose to the next Shareholders’ Meeting a dividend distribution of €1.35 per share, which will be payable on 20 May 2026, with dividend date set on 18 May 2026 (record
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 15:51:00 EET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 15:30:00 EET | Press release
Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and collaborations with leading pharmaceutical companies, including MSD since 2023 for MSIntuit, Waiv is establishing itself as a leader in translational medical AI. Waiv leverages a decade of Owkin's foundational medical AI research, including access to an extensive patient data net
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 15:30:00 EET | Press release
RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that helps sponsors gain earlier clarity, reduce risk, and execute complex programs
Andersen Consulting Broadens Capabilities Through Collaboration with Acumen Learning12.3.2026 15:30:00 EET | Press release
Andersen Consulting adds depth to its platform through a Collaboration Agreement with Acumen Learning, a U.S.-based firm specializing in business and financial acumen training for leadership development and sales performance. Founded in 2002, Acumen Learning works with Fortune 500 companies to enhance financial literacy, strategic thinking, and decision-making across all levels. Drawing from the principles in their best-selling books “Seeing the Big Picture” and “Business Acumen for Sales Success,” their programs equip leaders and teams to align decisions with corporate strategy, drive performance, and strengthen client relationships. Tailored for industries such as healthcare, energy, and technology, Acumen Learning empowers professionals to translate business knowledge into actionable impact. “At Acumen Learning, our mission is to empower individuals by creating business-savvy professionals who excel in their careers,” said CEO of Acumen Learning Kevin Cope. “Our courses pair practic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom